Effects of low-flow sevoflurane anesthesia on renal function: comparison with high-flow sevoflurane anesthesia and low-flow isoflurane anesthesia.

Background: The safety of low-flow sevoflurane anesthesia, during which CF2 = C(CF3)-O-CH2 F (compound A) is formed by sevoflurane degradation, in humans has been questioned because compound A is nephrotoxic in rats. Several reports have evaluated renal function after closed-circuit or low-flow sevoflurane anesthesia, using blood urea nitrogen (BUN) and serum creatinine as markers. However, these are not the more sensitive tests for detecting renal damage. This study assessed the effects of low-flow sevoflurane anesthesia on renal function using not only BUN and serum creatinine but also creatinine clearance and urinary excretion of kidney-specific enzymes, and it compared these values with those obtained in high-flow sevoflurane anesthesia and low-flow isoflurane anesthesia. Methods: Forty-eight patients with gastric cancer undergoing gastrectomy were studied. Patients were randomized to receive sevoflurane anesthesia with fresh gas flow of 1 l/min (low-flow sevoflurane group; n = 16) or 6–10 l/min (high-flow sevoflurane group; n = 16) or isoflurane anesthesia with a fresh gas flow of 1 l/min (low-flow isoflurane group; n = 16). In all groups, the carrier gas was oxygen/nitrous oxide in the ratio adjusted to ensure a fractional concentration of oxygen in inspired gas (FiO2) of more than 0.3. Fresh Baralyme was used in the low-flow sevoflurane and low-flow isoflurane groups. Glass balls were used instead in the high-flow sevoflurane group, with the fresh gas flow rate adjusted to eliminate rebreathing. The compound A concentration was measured by gas chromatography. Gas samples taken from the inspiratory limb of the circle system at 1-h intervals were analyzed. Blood samples were obtained before and on days 1, 2, and 3 after anesthesia to measure BUN and serum creatinine. Twenty-four-hour urine samples were collected before anesthesia and for each 24-h period from 0 to 72 h after anesthesia to measure creatinine, N-acetyl-beta-D-glucosaminidase, and alanine aminopeptidase. Results: The average inspired concentration of compound A was 20 +/- 7.8 ppm (mean +/- SD), and the average duration of exposure to this concentration was 6.11 +/- 1.77 h in the low-flow sevoflurane group. Postanesthesia BUN and serum creatinine concentrations decreased, creatinine clearance increased, and urinary N-acetyl-beta-D-glucosaminidase and alanine aminopeptidase excretion increased in all groups compared with preanesthesia values, but there were no significant differences between the low-flow sevoflurane, high-flow sevoflurane, and low-flow isoflurane groups for any renal function parameter at any time after anesthesia. Conclusions: The only difference between the low-flow and high-flow sevoflurane groups was compound A formation, and postanesthesia laboratory data showed no significant effects of compound A formation during sevoflurane anesthesia on renal function. No significant effects on renal function were observed in either the low-flow or high-flow sevoflurane groups compared with the low-flow isoflurane group.

[1]  M. W. Anders,et al.  Cysteine Conjugate beta-Lyase-dependent Biotransformation of the Cysteine S-Conjugates of the Sevoflurane Degradation Product Compound A in Human, Nonhuman Primate, and Rat Kidney Cytosol and Mitochondria , 1996, Anesthesiology.

[2]  E. Eger,et al.  Metabolism of Compound A by Renal Cysteine-S-Conjugate beta-Lyase Is Not the Mechanism of Compound A-Induced Renal Injury in the Rat , 1996, Anesthesia and analgesia.

[3]  T. Baillie,et al.  Identification in rat bile of glutathione conjugates of fluoromethyl 2,2-difluoro-1-(trifluoromethyl)vinyl ether, a nephrotoxic degradate of the anesthetic agent sevoflurane. , 1996, Chemical research in toxicology.

[4]  K. Ikeda,et al.  Renal and Hepatic Function in Surgical Patients After Low-Flow Sevoflurane or Isoflurane Anesthesia , 1996, Anesthesia and analgesia.

[5]  H. Higuchi,et al.  Renal Function in Patients with High Serum Fluoride Concentrations after Prolonged Sevoflurane Anesthesia , 1995, Anesthesiology.

[6]  M. Laster,et al.  Nephrotoxicity in Rats Undergoing a One-Hour Exposure to Compound A , 1995, Anesthesia and analgesia.

[7]  K. Ikeda,et al.  Effect of total flow rate on the concentration of degradation products generated by reaction between sevoflurane and soda lime. , 1995, British Journal of Anaesthesia.

[8]  T. Baillie,et al.  Nephrotoxicity of sevoflurane compound A [fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether] in rats: evidence for glutathione and cysteine conjugate formation and the role of renal cysteine conjugate beta-lyase. , 1995, Biochemical and biophysical research communications.

[9]  K. Ikeda,et al.  Plasma Inorganic Fluoride and Intracircuit Degradation Product Concentrations in Long‐Duration, Low‐Flow Sevoflurane Anesthesia , 1994, Anesthesia and analgesia.

[10]  K. Ikeda,et al.  Long‐duration, Low‐flow Sevoflurane Anesthesia Using Two Carbon Dioxide Absorbents: Quantification of Degradation Products in the Circuit , 1994, Anesthesiology.

[11]  E. Eger,et al.  Toxicity of Compound A in Rats: Effect of a 3‐Hour Administration , 1994, Anesthesiology.

[12]  E. Eger,et al.  Toxicity of Compound A in Rats: Effect of Increasing Duration of Administration , 1994, Anesthesiology.

[13]  E. Eger,et al.  The Degradation, Absorption, and Solubility of Volatile Anesthetics in Soda Lime Depend on Water Content , 1994, Anesthesia and analgesia.

[14]  K. Ikeda,et al.  Closed‐circuit Anesthesia with Sevoflurane in Humans Effects on Renal and Hepatic Function and Concentrations of Breakdown Products with Soda Lime in the Circuit , 1994, Anesthesiology.

[15]  Y. Ogasawara,et al.  Reaction of sevoflurane and its degradation products with soda lime. Toxicity of the byproducts. , 1992, Anesthesiology.

[16]  R. Mazze.  The safety of sevoflurane in humans. , 1992, Anesthesiology.

[17]  M. Malcomson,et al.  Quantification of the degradation products of sevoflurane in two CO2 absorbants during low-flow anesthesia in surgical patients. , 1992, Anesthesiology.

[18]  E. Eger,et al.  Absorption and Degradation of Sevoflurane and Isoflurane in a Conventional Anesthetic Circuit , 1991, Anesthesia and analgesia.

[19]  H. Shimada,et al.  Effect of N-benzyl-D-glucamine dithiocarbamate on renal toxicity of inorganic mercury in rats. , 1990, Chemical & pharmaceutical bulletin.

[20]  Jerome J. Schentag,et al.  The Increase in Urinary Alanine Aminopeptidase Excretion Associated with Enflurane Anesthesia Is Increased Further by Aminoglycosides , 1988, Anesthesia and analgesia.

[21]  K. Ikeda,et al.  The Minimum Alveolar Concentration (MAC) of Sevoflurane in Humans , 1987, Anesthesiology.

[22]  R. Gibey,et al.  Urinary N-acetyl-beta-D-glucosaminidase (NAG) isoenzyme profiles: a tool for evaluating nephrotoxicity of aminoglycosides and cephalosporins. , 1984, Clinica chimica acta; international journal of clinical chemistry.

[23]  P. Kind.  N-Acetyl-beta-D-glucosaminidase in urine of patients with renal disease, and after renal transplants and surgery. , 1982, Clinica chimica acta; international journal of clinical chemistry.

[24]  R. Gibey,et al.  Predictive value of urinary N-acetyl-beta-D-glucosaminidase (NAG), alanine-aminopeptidase (AAP) and beta-2-microglobulin (beta 2M) in evaluating nephrotoxicity of gentamicin. , 1981, Clinica chimica acta; international journal of clinical chemistry.

[25]  T. Maekawa,et al.  Clinical evaluation of urinary N-acetyl-beta-D-glucosaminidase activity in patients receiving aminoglycoside and cephalosporin drugs. , 1981, Research communications in chemical pathology and pharmacology.

[26]  R. G. Price,et al.  Urinary enzyme excretion during renal papillary necrosis induced in rats with ethyleneimine. , 1975, Chemico-biological interactions.

[27]  I. Stern,et al.  Sevoflurane: A New Inhalational Anesthetic Agent , 1975, Anesthesia and analgesia.

[28]  R. G. Price,et al.  Automated assay of N-acetyl-beta-glucosaminidase in normal and pathological human urine. , 1975, Clinica chimica acta; international journal of clinical chemistry.

[29]  R. Elashoff,et al.  Minimum alveolar concentrations (MAC) of isoflurande with and without nitrous oxide in patients of various ages. , 1975, Anesthesiology.